CYTR News and Press, CytRx Corporation From 07/01/19

CytRx Corporation (OTCQB: CYTR) , a biopharmaceutical research and development company with expertise in discovering and developing new therapeutics to treat patients with high unmet needs , according to the company’s website (see here: www.cytrx.com ). In this SNNLive In-Studio...

CytRx Corporation (OTCQB: CYTR) , a biopharmaceutical research and development company with expertise in discovering and developing new therapeutics to treat patients with high unmet needs , according to the company’s website (see here: www.cytrx.com ). In this SNNLive In-Studio...

LOS ANGELES , June 26, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the formulation, s...

DENVER, Colo., June 19, 2019- (24/7MarketNews via COMTEX) Venture Market News for June 19, 2019. Midas Gold Corp. Announces Closing of C$19.9 Million Bought Deal Public Offering VANCOUVER, British Columbia, June 19, 2019 (GLOBE NEWSWIRE) -- Midas Gold Corp. (TSX:MAX, OTCQX:MDRPF) (“Mi...

LOS ANGELES , June 19, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has updated the anticipated timing for submission of ...

LOS ANGELES , May 31, 2019 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will commence trading on the OTCQB Venture Market as of Tuesday, June 4, 2019 , under the same ticke...

CytRx (NASDAQ: CYTR ): Q1 GAAP EPS of -$0.04 beats by $0.02 . Cash and cash equivalents of $9.02M. Shares  +1.9% Press Release More news on: CytRx Corporation, Earnings news and commentary, Healthcare stocks news, ,

LOS ANGELES , May 15, 2019 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the first quarter ended March 31, 2019 , and provided an overview of recent accomplishmen...

LOS ANGELES , May 8, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the use of aldoxoru...

LOS ANGELES , May 2, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has provided clinical guidance on arimoclomol developm...